argenx SE (NASDAQ: ARGX) Stock Competitors & Peer Comparison
See ARGX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ARGX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ARGX | $1,038.12 | +0.51% | 64.6B | 93.69 | $11.08 | N/A |
| VRTX | $540.26 | -2.14% | 137.1B | 28.39 | $19.03 | N/A |
| REGN | $826.64 | -1.69% | 85.2B | 18.12 | $45.63 | +0.44% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| MRNA | $133.32 | -23.55% | 52.9B | -16.36 | -$8.15 | N/A |
| RVMDW | $12.27 | -0.16% | 47.1B | -1.66 | -$7.21 | N/A |
| RVMD | $211.74 | -1.36% | 45B | -24.01 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $369.16 | -2.04% | 39.4B | 64.99 | $5.68 | N/A |
| ALNY | $229.30 | -5.49% | 30.7B | 41.32 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ARGX vs VRTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, VRTX has a market cap of 137.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while VRTX trades at $540.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas VRTX's P/E ratio is 28.39. In terms of profitability, ARGX's ROE is +0.32%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ARGX is similarly volatile compared to VRTX. This indicates similar risk in terms of short-term price fluctuations for ARGX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ARGX vs REGN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, REGN has a market cap of 85.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while REGN trades at $826.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas REGN's P/E ratio is 18.12. In terms of profitability, ARGX's ROE is +0.32%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ARGX is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ARGX vs VRNA Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARGX's ROE is +0.32%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, ARGX is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check VRNA's competition here
Moderna, Inc. (NASDAQ: MRNA)
ARGX vs MRNA Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, MRNA has a market cap of 52.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while MRNA trades at $133.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas MRNA's P/E ratio is -16.36. In terms of profitability, ARGX's ROE is +0.32%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ARGX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ARGX vs RVMDW Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, RVMDW has a market cap of 47.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while RVMDW trades at $12.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas RVMDW's P/E ratio is -1.66. In terms of profitability, ARGX's ROE is +0.32%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ARGX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ARGX vs RVMD Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, RVMD has a market cap of 45B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while RVMD trades at $211.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas RVMD's P/E ratio is -24.01. In terms of profitability, ARGX's ROE is +0.32%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ARGX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
ARGX vs SGEN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARGX's ROE is +0.32%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARGX is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
ARGX vs ONC Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ONC has a market cap of 39.4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ONC trades at $369.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ONC's P/E ratio is 64.99. In terms of profitability, ARGX's ROE is +0.32%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ARGX is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ARGX vs ALNY Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ALNY has a market cap of 30.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ALNY trades at $229.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ALNY's P/E ratio is 41.32. In terms of profitability, ARGX's ROE is +0.32%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ARGX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
ARGX vs BNTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, BNTX has a market cap of 27.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while BNTX trades at $110.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas BNTX's P/E ratio is -20.07. In terms of profitability, ARGX's ROE is +0.32%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ARGX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
ARGX vs INSM Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, INSM has a market cap of 27.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while INSM trades at $125.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas INSM's P/E ratio is -27.37. In terms of profitability, ARGX's ROE is +0.32%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ARGX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ARGX vs ROIV Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ROIV has a market cap of 26.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ROIV trades at $36.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ROIV's P/E ratio is -35.05. In terms of profitability, ARGX's ROE is +0.32%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ARGX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
ARGX vs INCY Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, INCY has a market cap of 25.8B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while INCY trades at $127.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas INCY's P/E ratio is 17.10. In terms of profitability, ARGX's ROE is +0.32%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ARGX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ARGX vs UTHR Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, UTHR has a market cap of 22.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while UTHR trades at $521.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas UTHR's P/E ratio is 18.64. In terms of profitability, ARGX's ROE is +0.32%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ARGX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
ARGX vs GMAB Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, GMAB has a market cap of 20.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while GMAB trades at $33.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas GMAB's P/E ratio is 25.18. In terms of profitability, ARGX's ROE is +0.32%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ARGX is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ARGX vs BGNE Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARGX's ROE is +0.32%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ARGX is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ARGX vs DNA-WT Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.32%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ARGX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNA-WT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ARGX vs BBIO Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, BBIO has a market cap of 16.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while BBIO trades at $82.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas BBIO's P/E ratio is -22.18. In terms of profitability, ARGX's ROE is +0.32%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ARGX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ARGX vs ASND Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ASND has a market cap of 15.8B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ASND trades at $254.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ASND's P/E ratio is -105.29. In terms of profitability, ARGX's ROE is +0.32%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ARGX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ARGX vs JAZZ Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while JAZZ trades at $248.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas JAZZ's P/E ratio is 9.27. In terms of profitability, ARGX's ROE is +0.32%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ARGX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ARGX vs NBIX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while NBIX trades at $152.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas NBIX's P/E ratio is 22.10. In terms of profitability, ARGX's ROE is +0.32%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ARGX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ARGX vs EXEL Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, EXEL has a market cap of 13.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while EXEL trades at $53.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas EXEL's P/E ratio is 15.34. In terms of profitability, ARGX's ROE is +0.32%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ARGX is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ARGX vs BMRN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, BMRN has a market cap of 13.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while BMRN trades at $67.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas BMRN's P/E ratio is 32.54. In terms of profitability, ARGX's ROE is +0.32%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ARGX is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ARGX vs KRTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARGX's ROE is +0.32%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARGX is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ARGX vs HALO Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, HALO has a market cap of 12.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while HALO trades at $106.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas HALO's P/E ratio is 19.80. In terms of profitability, ARGX's ROE is +0.32%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ARGX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check HALO's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ARGX vs ARWR Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ARWR has a market cap of 12.3B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ARWR trades at $87.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ARWR's P/E ratio is -38.88. In terms of profitability, ARGX's ROE is +0.32%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ARGX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ARGX vs MDGL Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, MDGL has a market cap of 12B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while MDGL trades at $519.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas MDGL's P/E ratio is -40.55. In terms of profitability, ARGX's ROE is +0.32%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ARGX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ARGX vs TECH Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while TECH trades at $72.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas TECH's P/E ratio is 37.26. In terms of profitability, ARGX's ROE is +0.32%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ARGX is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ARGX vs RNAM Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARGX's ROE is +0.32%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, ARGX is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ARGX vs AXSM Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while AXSM trades at $208.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas AXSM's P/E ratio is -54.32. In terms of profitability, ARGX's ROE is +0.32%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ARGX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check AXSM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ARGX vs PRAX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, PRAX has a market cap of 10.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while PRAX trades at $364.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas PRAX's P/E ratio is -28.20. In terms of profitability, ARGX's ROE is +0.32%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ARGX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ARGX vs KYMR Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, KYMR has a market cap of 10B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while KYMR trades at $121.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas KYMR's P/E ratio is -37.97. In terms of profitability, ARGX's ROE is +0.32%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ARGX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ARGX vs PTGX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while PTGX trades at $150.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas PTGX's P/E ratio is 150.43. In terms of profitability, ARGX's ROE is +0.32%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ARGX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PTGX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ARGX vs KRYS Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while KRYS trades at $337.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas KRYS's P/E ratio is 42.23. In terms of profitability, ARGX's ROE is +0.32%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ARGX vs SMMT Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, SMMT has a market cap of 9.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while SMMT trades at $12.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas SMMT's P/E ratio is -7.77. In terms of profitability, ARGX's ROE is +0.32%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ARGX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SMMT's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ARGX vs IONS Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, IONS has a market cap of 9.8B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while IONS trades at $58.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas IONS's P/E ratio is -34.16. In terms of profitability, ARGX's ROE is +0.32%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ARGX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IONS's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ARGX vs CYTK Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CYTK trades at $77.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CYTK's P/E ratio is -10.69. In terms of profitability, ARGX's ROE is +0.32%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ARGX is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ARGX vs RXDX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARGX's ROE is +0.32%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RXDX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ARGX vs SYRE Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, SYRE has a market cap of 9.4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while SYRE trades at $107.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas SYRE's P/E ratio is -55.28. In terms of profitability, ARGX's ROE is +0.32%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ARGX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ARGX vs IMVT Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, IMVT has a market cap of 9.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while IMVT trades at $44.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas IMVT's P/E ratio is -15.73. In terms of profitability, ARGX's ROE is +0.32%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ARGX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IMVT's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ARGX vs NUVL Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARGX's ROE is +0.32%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARGX is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ARGX vs CRNX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CRNX trades at $84.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CRNX's P/E ratio is -16.80. In terms of profitability, ARGX's ROE is +0.32%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARGX is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CRNX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ARGX vs PCVX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while PCVX trades at $61.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas PCVX's P/E ratio is -8.04. In terms of profitability, ARGX's ROE is +0.32%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ARGX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ARGX vs IMGN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARGX's ROE is +0.32%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARGX is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
ARGX vs ABVX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ABVX trades at $118.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ABVX's P/E ratio is -61.95. In terms of profitability, ARGX's ROE is +0.32%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, ARGX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ARGX vs BPMC Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARGX's ROE is +0.32%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARGX is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ARGX vs APGE Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while APGE trades at $134.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas APGE's P/E ratio is -31.12. In terms of profitability, ARGX's ROE is +0.32%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ARGX is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check APGE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ARGX vs IBRX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, IBRX has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while IBRX trades at $7.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas IBRX's P/E ratio is -8.08. In terms of profitability, ARGX's ROE is +0.32%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ARGX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IBRX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ARGX vs CERE Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARGX's ROE is +0.32%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARGX is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CERE's competition here
Alkermes plc (NASDAQ: ALKS)
ARGX vs ALKS Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ALKS has a market cap of 8.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ALKS trades at $48.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ALKS's P/E ratio is 50.55. In terms of profitability, ARGX's ROE is +0.32%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, ARGX is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ALKS's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ARGX vs TGTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, TGTX has a market cap of 7.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while TGTX trades at $50.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas TGTX's P/E ratio is 18.32. In terms of profitability, ARGX's ROE is +0.32%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ARGX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TGTX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ARGX vs RYTM Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while RYTM trades at $108.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas RYTM's P/E ratio is -35.02. In terms of profitability, ARGX's ROE is +0.32%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ARGX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
ARGX vs MTSR Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARGX's ROE is +0.32%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, ARGX is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ARGX vs CAI Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CAI trades at $24.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CAI's P/E ratio is 69.06. In terms of profitability, ARGX's ROE is +0.32%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ARGX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CAI's competition here
CG Oncology Inc. (NASDAQ: CGON)
ARGX vs CGON Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CGON has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CGON trades at $77.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CGON's P/E ratio is -28.85. In terms of profitability, ARGX's ROE is +0.32%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ARGX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
ARGX vs MRUS Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARGX's ROE is +0.32%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, ARGX is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ARGX vs ACLX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARGX's ROE is +0.32%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, ARGX is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ARGX vs SRRK Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while SRRK trades at $55.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas SRRK's P/E ratio is -16.01. In terms of profitability, ARGX's ROE is +0.32%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ARGX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check SRRK's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ARGX vs RETA Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARGX's ROE is +0.32%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARGX is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ARGX vs BLTE Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while BLTE trades at $161.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas BLTE's P/E ratio is -86.60. In terms of profitability, ARGX's ROE is +0.32%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, ARGX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check BLTE's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ARGX vs ORKA Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ORKA has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ORKA trades at $104.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ORKA's P/E ratio is -54.05. In terms of profitability, ARGX's ROE is +0.32%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ARGX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ORKA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ARGX vs CNTA Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARGX's ROE is +0.32%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARGX is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CNTA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ARGX vs PTCT Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while PTCT trades at $70.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas PTCT's P/E ratio is -31.62. In terms of profitability, ARGX's ROE is +0.32%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ARGX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PTCT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ARGX vs DNTH Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, DNTH has a market cap of 6.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while DNTH trades at $109.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas DNTH's P/E ratio is -26.39. In terms of profitability, ARGX's ROE is +0.32%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ARGX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ARGX vs COGT Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, COGT has a market cap of 6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while COGT trades at $35.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas COGT's P/E ratio is -16.73. In terms of profitability, ARGX's ROE is +0.32%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ARGX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check COGT's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ARGX vs DFTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, DFTX has a market cap of 6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while DFTX trades at $45.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARGX's ROE is +0.32%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ARGX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DFTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ARGX vs TVTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, TVTX has a market cap of 6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while TVTX trades at $64.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas TVTX's P/E ratio is -143.24. In terms of profitability, ARGX's ROE is +0.32%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ARGX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TVTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
ARGX vs ERAS Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ERAS has a market cap of 5.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ERAS trades at $17.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ERAS's P/E ratio is -18.37. In terms of profitability, ARGX's ROE is +0.32%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ARGX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ERAS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ARGX vs MIRM Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while MIRM trades at $97.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas MIRM's P/E ratio is -6.67. In terms of profitability, ARGX's ROE is +0.32%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ARGX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ARGX vs XENE Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while XENE trades at $59.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas XENE's P/E ratio is -12.71. In terms of profitability, ARGX's ROE is +0.32%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ARGX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ARGX vs LGND Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while LGND trades at $287.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas LGND's P/E ratio is 31.55. In terms of profitability, ARGX's ROE is +0.32%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ARGX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ARGX vs CDTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARGX's ROE is +0.32%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, ARGX is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CDTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ARGX vs CRSP Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CRSP trades at $58.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CRSP's P/E ratio is -12.21. In terms of profitability, ARGX's ROE is +0.32%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ARGX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CRSP's competition here
Abcam plc (NASDAQ: ABCM)
ARGX vs ABCM Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARGX's ROE is +0.32%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARGX is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ARGX vs ISEE Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARGX's ROE is +0.32%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARGX is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ARGX vs APLS Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARGX's ROE is +0.32%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARGX is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
ARGX vs ACAD Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ACAD has a market cap of 5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ACAD trades at $29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ACAD's P/E ratio is 13.08. In terms of profitability, ARGX's ROE is +0.32%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, ARGX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
ARGX vs DYN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while DYN trades at $25.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas DYN's P/E ratio is -8.07. In terms of profitability, ARGX's ROE is +0.32%, compared to DYN's ROE of -0.64%. Regarding short-term risk, ARGX is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ARGX vs TERN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARGX's ROE is +0.32%, compared to TERN's ROE of -0.20%. Regarding short-term risk, ARGX is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ARGX vs EWTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, EWTX has a market cap of 4.7B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while EWTX trades at $43.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas EWTX's P/E ratio is -23.40. In terms of profitability, ARGX's ROE is +0.32%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ARGX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
ARGX vs PBLS Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while PBLS trades at $39.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas PBLS's P/E ratio is -44.98. In terms of profitability, ARGX's ROE is +0.32%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, ARGX is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ARGX vs FOLD Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARGX's ROE is +0.32%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, ARGX is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ARGX vs AKRO Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARGX's ROE is +0.32%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, ARGX is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ARGX vs ALPN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARGX's ROE is +0.32%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARGX is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
ARGX vs CELC Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CELC trades at $90.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CELC's P/E ratio is -21.06. In terms of profitability, ARGX's ROE is +0.32%, compared to CELC's ROE of -3.51%. Regarding short-term risk, ARGX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check CELC's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
ARGX vs AMLX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, AMLX has a market cap of 4.4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while AMLX trades at $39.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas AMLX's P/E ratio is -26.44. In terms of profitability, ARGX's ROE is +0.32%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, ARGX is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check AMLX's competition here
Veradermics, Incorporated (NYSE: MANE)
ARGX vs MANE Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while MANE trades at $105.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas MANE's P/E ratio is -33.47. In terms of profitability, ARGX's ROE is +0.32%, compared to MANE's ROE of -0.29%. Regarding short-term risk, ARGX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check MANE's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ARGX vs RLAY Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while RLAY trades at $19.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas RLAY's P/E ratio is -12.55. In terms of profitability, ARGX's ROE is +0.32%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ARGX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check RLAY's competition here
Opthea Limited (NASDAQ: OPT)
ARGX vs OPT Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARGX's ROE is +0.32%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARGX is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ARGX vs PRTC Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ARGX's ROE is +0.32%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ARGX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check PRTC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
ARGX vs ELVN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ELVN trades at $58.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ELVN's P/E ratio is -35.28. In terms of profitability, ARGX's ROE is +0.32%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, ARGX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ELVN's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ARGX vs TLX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, TLX has a market cap of 4.2B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while TLX trades at $12.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas TLX's P/E ratio is -675.00. In terms of profitability, ARGX's ROE is +0.32%, compared to TLX's ROE of -0.02%. Regarding short-term risk, ARGX is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check TLX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ARGX vs MRTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARGX's ROE is +0.32%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARGX is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check MRTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ARGX vs ADPT Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while ADPT trades at $25.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas ADPT's P/E ratio is -62.05. In terms of profitability, ARGX's ROE is +0.32%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ARGX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check ADPT's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ARGX vs IOVA Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, IOVA has a market cap of 4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while IOVA trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas IOVA's P/E ratio is -9.46. In terms of profitability, ARGX's ROE is +0.32%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ARGX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check IOVA's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
ARGX vs VKTX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while VKTX trades at $34.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas VKTX's P/E ratio is -8.30. In terms of profitability, ARGX's ROE is +0.32%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, ARGX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
ARGX vs DNLI Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, DNLI has a market cap of 4B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while DNLI trades at $24.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas DNLI's P/E ratio is -8.66. In terms of profitability, ARGX's ROE is +0.32%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, ARGX is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check DNLI's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ARGX vs LEGN Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, LEGN has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while LEGN trades at $21.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas LEGN's P/E ratio is -31.26. In terms of profitability, ARGX's ROE is +0.32%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ARGX is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for ARGX.Check LEGN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ARGX vs CPRX Comparison August 2026
argenx SE (NASDAQ: ARGX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARGX stands at 64.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARGX is priced at $1,038.12 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARGX currently has a P/E ratio of 93.69, whereas CPRX's P/E ratio is 12.30. In terms of profitability, ARGX's ROE is +0.32%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARGX is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ARGX.Check CPRX's competition here